Defence Therapeutics Inc.
DTC
CNSX
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 75.72% | 80.30% | |||
| Depreciation & Amortization | 13.01% | -3.15% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 91.99% | 29.44% | |||
| Operating Income | -91.99% | -29.44% | |||
| Income Before Tax | -26.23% | -15.36% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -26.23% | -15.36% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -26.23% | -15.36% | |||
| EBIT | -91.99% | -29.44% | |||
| EBITDA | -95.73% | -28.91% | |||
| EPS Basic | -13.33% | -8.87% | |||
| Normalized Basic EPS | 9.18% | -25.64% | |||
| EPS Diluted | -13.33% | -8.87% | |||
| Normalized Diluted EPS | 9.18% | -25.64% | |||
| Average Basic Shares Outstanding | 11.16% | 6.53% | |||
| Average Diluted Shares Outstanding | 11.16% | 6.53% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||